Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06911710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Study acronym: CAR-T
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 4, 2025 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
Trial Details
NCT Number NCT06911710
Lead Sponsor Tianjin Medical University General Hospital
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions
(from sponsor)		 Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple, B-ALL, T-ALL/Lymphoma, T-lymphocyte Lymphoma
Related terms Leukemia, Myeloid, Acute, Lymphoma, Multiple Myeloma
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov